Table 2.

Solutes measured by HPLC and urea

Solute	Dialysis Intact Colon (n = 9)	Dialysis Colectomy (n = 6)	Normal Control (n = 7 to 10)
PCS
plasma pretreatment mg/dl	4.1 ± 1.6a,b	0.06 ± 0.09	0.19 ± 0.13
reduction ratio	30 ± 7	–	–
IS
plasma pretreatment mg/dl	2.8 ± 1.3a,b	0.08 ± 0.06	0.06 ± 0.02
reduction ratio	33 ± 7	31 ± 11	–
KYNA
plasma pretreatment nM	799 ± 404b	634 ± 292b	29 ± 7
reduction ratio	36 ± 7	39 ± 16	–
Hippurate
plasma pretreatment mg/dl	7.9 ± 4.5b	4.6 ± 5.9b	0.3 ± 0.2
reduction ratio	68 ± 4	72 ± 19	–
DMA
plasma pretreatment μg/dl	1032 ± 155b	890 ± 103b	218 ± 33
reduction ratio	38 ± 10	43 ± 7	–
MMA
plasma pretreatment μg/dl	58 ± 10b	54 ± 9b	32 ± 4
reduction ratio	30 ± 10	23 ± 6	–
Urea
plasma pretreatment mg/dl	50 ± 8b	43 ± 16b	14 ± 3
reduction ratio	74 ± 4	78 ± 7	–

Values are mean ± SD. The plasma PCS concentration was below the limits of detection in one normal subject and in three pretreatment samples and four post-treatment samples from dialysis patients without colons; a reduction ratio for PCS in the dialysis colectomy group was therefore not determined. The plasma hippurate was below the limits of detection in one patient without a colon.

^aP < 0.05 dialysis intact colon group versus dialysis colectomy group.

^bP < 0.05 dialysis intact colon group or dialysis colectomy group versus normal control group.